NCT05238883 2025-11-21
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
Phase 1 Active not recruiting
HiFiBiO Therapeutics
HiFiBiO Therapeutics
BeiGene
Peking University Cancer Hospital & Institute
Novartis
BGI, China
Tianjin Medical University Cancer Institute and Hospital
Shanghai Zhongshan Hospital